Processa Pharmaceuticals
PCSA
11 hedge funds and large institutions have $393K invested in Processa Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
10% more funds holding
Funds holding: 10 → 11 (+1)
0.56% more ownership
Funds ownership: 6.68% → 7.25% (+0.56%)
12% less capital invested
Capital invested by funds: $448K → $393K (-$55.7K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$55.2K |
| 2 |
CCM
Connective Capital Management
Palo Alto,
California
|
+$37.6K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$34.4K |
| 4 |
Jane Street
New York
|
+$34.3K |
| 5 |
SG
StoneX Group
New York
|
+$29.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$7.3K |
| 2 |
Citigroup
New York
|
-$35 |
| 3 |
Wells Fargo
San Francisco,
California
|
-$15 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CCM
1
Connective Capital Management
Palo Alto,
California
| $164K | +$37.6K | +14,538 | +21% |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $42.4K | -$7.3K | -2,818 | -11% |
|
|
3
Citadel Advisors
Miami,
Florida
| $40.9K | +$55.2K | +21,306 | New |
|
|
SG
4
StoneX Group
New York
| $29.6K | +$29.6K | +11,437 | New |
|
|
XT
5
XTX Topco
George Town,
Cayman Islands
| $25.5K | +$34.4K | +13,292 | New |
|
|
6
Jane Street
New York
| $25.5K | +$34.3K | +13,264 | New |
|
7
Vanguard Capital Management
Malvern,
Pennsylvania
| $24.4K | – | – | – |
|
8
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
| $20.8K | – | – | – |
|
9
UBS Group
Zurich,
Switzerland
| $15K | +$13.6K | +5,263 | +208% |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $4.8K | +$4.09K | +1,581 | +172% |
|
11
Jones Financial Companies
Des Peres,
Missouri
| $13 | – | – | – |
|
|
12
Citigroup
New York
| – | -$35 | -14 | Closed |
|
|
13
Wells Fargo
San Francisco,
California
| – | -$15 | -6 | Closed |
|
PCSA Hedge Fund Activity: Q2 2026 in Review
11 of the 8,153 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q2 2026, worth a combined $393K — down 12% from $448K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PCSA positions and 2 closed out — a net gain of 2 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $55.2K. The largest seller was Geode Capital Management, cutting an estimated $7.3K.
- 11 institutional investors held Processa Pharmaceuticals (PCSA) as of Q2 2026, up from 10 in Q1 2026.
- Funds reported $393K of Processa Pharmaceuticals stock for Q2 2026, down 12% quarter-over-quarter.
- 4 funds opened new Processa Pharmaceuticals positions in Q2 2026 and 2 closed out, a net change of +2 holders.
- The largest Processa Pharmaceuticals buyer in Q2 2026 was Citadel Advisors, an estimated $55.2K added.
- The largest Processa Pharmaceuticals seller in Q2 2026 was Geode Capital Management, an estimated $7.3K sold.
Based on aggregated 13F filings for Q2 2026.